Menu

Top Stories

Published on Thursday, April 11, 2019

Moderated discussion: “Advancing the innovation ecosystem: Working together for patients,” in Washington, DC

Moderated discussion: “Advancing the innovation ecosystem: Working together for patients,” in Washington, DC

On April 3, 2019, Francis Collins, MD, PhD, director of the National Institutes of Health (NIH), Mikael Dolsten, MD, PhD, chief scientific officer and president, Worldwide Research, Development and Medical, Pfizer, joined in a discussion led by Susan Dentzer, visiting fellow at the Robert J. Margolis Center for Health Policy, Duke University, in Washington DC.

Photo: Francis Collins, MD, PhD, director of the NIH (left) and author Alejandro Hernandez, editorial manager of the Alpha-1 Foundation (right)

For 60 minutes, Collins, Dolsten, and Dentzer engaged in a conversation with the theme of: “Advancing the innovation ecosystem: working together for patients,” where they emphasized the need for continued collaboration between the private and public sectors, along with the patient community, in order to advance new and emerging technologies and innovative approaches for potentially life-saving treatments and new outcomes in medicine.

“We are currently living in remarkable times with amazing things happening in areas such as cancer immuno-therapy, gene therapy, and gene editing. The things that are happening right now, I had no idea they would even be possible just five or six years ago,” expressed Collins when asked about the current position “the ecosystem,” as they described the collaboration between the private and public sectors with small biotech companies; an ecosystem with symbiotic characteristics where all contributors play an important role in a tremendous team effort, in medical research.

Collins and Dolsten agreed on the importance of advocacy groups and organizations as well as the patient community, in being part of the process for better outcomes and the ability to bring new and potential treatments for various conditions to the clinic, including rare diseases, such as Alpha-1 Antitrypsin Deficiency (Alpha-1). 

“We need you, the patient community, you are the reason we have gotten this far,” said Collins.

“One of the most important resources needed for this ecosystem to strive is you, the patient. We need to line-up our resources and keep the ecosystem going, including the patient community. There is no one better to bring together what others (physicians) can do than patients: you inspire all of us,” expressed Dolsten.

The Alpha-1 Foundation applauds and supports these types of initiatives, in which patients become partners and are of vital importance for therapeutic development. 

The panel also mentioned that it is critical to spread awareness and education in the medical community, and being able to have early diagnosis and detection, while mentioning the Accelerating Medicines Partnership (AMP), a public-private partnership between the NIH, the U.S. Food and Drug Administration (FDA), multiple biopharmaceutical, and life science companies, as well as non-profit organizations to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets for therapeutics.

The ultimate goal of AMP is to increase the number of new diagnostics and therapies for patients and reduce the time and cost of developing them.

“Patient participation is critical for AMP, especially to remind us what we are doing and why-and-who we are doing it for,” said Collins, who also mentioned the Foundation for the National Institutes of Health (FNIH) as being instrumental in bringing together funds and resources from both the private and public sectors, to work in mutual collaboration in research projects that will ultimately benefit the patient community.

The Alpha-1 Foundation applauds these types of initiatives that support research and bring innovative approaches to the table for the benefit of the patient community, as we are committed to finding a cure for Alpha-1 and improving the lives of Alphas, and those affected by the condition, worldwide.

For more information, please visit the Collaboration Ecosystem website and the AMP website.


Print

Alpha friend and leader Jim Quill passes away

Monday, January 14, 2019
It is with a heavy heart that the Alpha-1 Foundation shares the passing of a dear friend and leader, James Quill on Sunday, January 13th, 2019 in Bluffton, South Carolina. He was 67. Jim was on the Alpha-1 Foundation Board of Directors since...
Divider

Shire is now part of Takeda

Tuesday, January 8, 2019
Takeda Pharmaceutical Company Ltd. and Shire Biotechnology company took an exciting step forward by completing the acquisition that was announced in 2018 and becoming a global biopharmaceutical company headquartered in...
Divider

Apic Bio announces $40M financing to advance novel gene therapies for rare genetic disorders

Monday, January 7, 2019
Apic Bio, Inc., an innovative gene therapy company developing novel treatment options for patients with rare genetic diseases, announced the completion of a $40 million Series A financing led by Morningside Venture Investments, Ltd. Existing...
Divider

FDA sends warnings after several people hospitalized with infections from stem cell shots

Friday, December 21, 2018
Twelve patients became seriously ill after receiving injections that supposedly contained stem cells from umbilical cord blood, according to the U.S. Food and Drug Administration (FDA), which issued a warning to the California company, Genetech,...
Divider

Near and far, the 2018 Virtual Walk raised the bar

Tuesday, December 18, 2018
Alphas from all over the United States joined together in November for the annual Alpha-1 Foundation Virtual Walk. For 30 days, in 36 states, friends and family supported one strong mission to find a cure. From near and far, 68 teams and 40 solo...
Divider

Giants in chest medicine: Gerard M. Turino, MD

Thursday, December 13, 2018
“My initial encounter with Gerry Turino took place in 1976, during my first year as a pathology intern at Columbia-Presbyterian Hospital. I was referred to him by a colleague, after mentioning my interest in connective tissue research. When...
Divider

Medicare Open Enrollment for 2019 coverage

Thursday, December 6, 2018
Medicare health and drug plan holders can make changes annually on costs, coverage, and which providers and pharmacies are in their networks. From October 15th, 2018, through December 7th, 2018, people with Medicare can change their health plan...
Divider

Zemaira update

Tuesday, December 4, 2018
The Alpha-1 Foundation was informed by CSL Behring that Zemaira, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1), returned to normal distribution on Monday, December 3rd, 2018. This is...
Divider

Alpha-1 Foundation announces new Director of Communications

Monday, December 3, 2018
The Alpha-1 Foundation announces the appointment of Jeanne Kushner as the new Director of Communications. Kushner leaves her position as Senior Director of Development at the Foundation where she has overseen the Development Department and...
Divider

Alpha-1 friend Lynn Lothian passes away

Monday, November 26, 2018
It is with a heavy heart that the Alpha-1 Foundation shares the passing of Lynn Martine Lothian at the age of 61. Lynn began her leadership in the Alpha-1 community in 2007, when she started leading the Maryland Alpha-1 support group. When she...
Divider

Looking beyond mortality in transplantation outcomes

Tuesday, November 20, 2018
To the Centers for Medicare and Medicaid Services (CMS), whose benchmarks are the basis for whether a program is certified as a transplant center, success means being alive one year after transplantation, regardless of the quality of life of the...
Divider

Gordon L. Snider Critical Issues Workshop to focus on the COPD National Action Plan and Alpha-1

Wednesday, November 14, 2018
The 17th Gordon L. Snider Critical Issues Workshop, titled “The Alpha-1 Foundation Approach to the COPD National Action Plan” is being held on November 15th, 2018, in New York, NY, and includes expert representation from academia,...
Divider
12345678910Last

Article Search

Enter keywords in text box and click Search button for results.

Archive